10005- A Phase 2 Study of Anti-PD-L1 Antibody MPDL3280A (Atezolizumab) in Alveolar Soft Part Sarcoma
Study of Atezolizumab in Alveolar Soft Part Sarcoma
Sponsor: ETCTN
Enrolling: Male and Female Patients
IRB Number: AAAR3626
U.S. Govt. ID: NCT03141684
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety and effectiveness of the study drug called atezolizumab in patients with alveolar soft part sarcoma. Atezolizumab works by unblocking your immune system, allowing your immune system cells to recognize and then attack your tumor cells. Atezolizumab could shrink your cancer but it could also have side effects. Researchers hope to learn if the study drug will shrink the cancer by at least one-quarter compared to its present size. Atezolizumab is approved for use by the Food and Drug Administration (FDA) for a specific type of cancer, but it is not FDA-approved for your type of tumor and is still an experimental drug.
Investigator
Gary Schwartz, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with Alveolar Soft Part Sarcoma? Yes No
Are you able to walk, care for yourself, and do light physical activities like light housework or office work? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162